Everything You Need to Know About HPV Vaccination and Cervical Cancer Prevention in India

Cervical cancer is not a disease that arrives without warning or without a known cause. In most cases, it is the long-term consequence of an infection that could have been prevented. That makes it exceptional among cancers, and it makes the gap between what is scientifically possible and what is actually happening in India one of the most consequential public health issues in the country today.

India accounts for roughly one in five cervical cancer deaths globally, despite the existence of safe and effective vaccines that have been available for well over a decade. Closing that gap requires more than vaccines alone. It requires awareness of what HPV is, who is at risk, what the vaccination schedule looks like, what the vaccines currently available in India protect against, and why cervical screening cannot be abandoned even after vaccination. This article brings all of that together in one place.

Key Takeaways

● Nearly all cervical cancer cases are caused by persistent infection with high-risk human papillomavirus strains, making it one of the most preventable cancers through vaccination and screening.

● India records approximately 1.24 lakh new cervical cancer cases and over 77,000 deaths each year, a burden that disproportionately affects women in rural and semi-urban populations.

● Three HPV vaccines are currently relevant in India: Cervavac Vaccine, Gardasil Injection, and Cervarix Injection, each differing in strain coverage and approved age groups.

● The most effective window for HPV vaccination is between 9 and 14 years of age, when a two-dose schedule is sufficient and the immune response is strongest.

● India's national immunisation programme now includes HPV vaccination for adolescent girls, marking a significant step toward population-level cervical cancer prevention.

● Vaccination and cervical cancer screening are complementary strategies and both remain necessary throughout a woman's adult life.

The Cervical Cancer Burden in India

The scale of cervical cancer in India is not abstract. According to GLOBOCAN 2022 data, India recorded an estimated 1,23,907 new cervical cancer cases and 77,348 deaths in that year alone. Cervical cancer is the second most common cancer among Indian women overall, and the most common cancer in women between the ages of 15 and 44, the years that represent the most economically and socially productive phase of a woman's life.

The burden is not evenly distributed. Women in rural areas, where organised screening programmes are sparse, where awareness of HPV is low, and where access to specialty healthcare is limited, bear a disproportionate share of diagnoses and deaths. Late-stage presentation is common in these settings, and when cervical cancer is detected at an advanced stage, treatment is complex, outcomes are significantly worse, and the disruption to families and communities is substantial.

The economic and social consequences compound the clinical ones. A 2019 analysis of cancer-related productivity losses in India identified cervical cancer as one of the leading contributors to premature mortality-related economic loss among Indian women. These are deaths that, in the majority of cases, need not occur.

What HPV Is and How It Leads to Cervical Cancer

Human papillomavirus is a group of over 200 related viruses, of which approximately 14 are considered high-risk for cancer development. It is transmitted primarily through skin-to-skin contact during sexual activity and is the most common sexually transmitted infection worldwide. Most infections resolve on their own within one to two years without causing any symptoms or long-term consequences.

The problem arises with persistent infection. When high-risk HPV strains, particularly HPV 16 and HPV 18, remain present in cervical tissue over an extended period, they can cause gradual changes to the DNA of cervical cells. These changes progress through stages of precancerous abnormality, known as cervical intraepithelial neoplasia, before potentially developing into invasive cervical cancer. This progression typically takes 10 to 15 years, which is precisely the window in which screening can interrupt the process and vaccination can prevent it from beginning.

HPV 16 and 18 together are responsible for approximately 70 percent of cervical cancer cases globally. In India, studies have confirmed a similar pattern, with HPV 16 being the dominant strain in invasive cervical cancer cases. Beyond cervical cancer, HPV also causes cancers of the vulva, vagina, anus, penis, and oropharynx, as well as genital warts caused by the lower-risk strains HPV 6 and 11.

The HPV Vaccines Currently Available in India

Three vaccines are relevant to HPV prevention in the Indian context, and each has a distinct profile in terms of what it covers and who it is approved for.

Cervavac Vaccine, developed and manufactured by the Serum Institute of India, is the country's first indigenously produced HPV vaccine. It is quadrivalent, targeting HPV strains 6, 11, 16, and 18. It was granted approval by India's Central Drugs Standard Control Organisation in 2022, and its inclusion in the national immunisation programme has made it the most accessible HPV vaccine in India, available at government health centres and school-based immunisation drives at a fraction of the cost of imported alternatives. Cervavac is approved for females aged 9 to 26 years.

Gardasil Injection, manufactured by Merck, is available in two versions. The quadrivalent formulation covers the same four strains as Cervavac. Gardasil 9, the more widely recommended version, extends protection to nine HPV strains by adding HPV 31, 33, 45, 52, and 58, bringing the total preventable fraction of cervical cancer cases to approximately 90 percent. Gardasil 9 is approved for both males and females aged 9 to 45, making it the only HPV vaccine in this group with approval for male recipients and for adults beyond 26 years of age. It is available through private clinics and specialty pharmacies such as MrMed, which stocks specialty and preventive medicines including imported oncology and vaccine products.

Cervarix Injection, developed by GlaxoSmithKline, is a bivalent vaccine targeting HPV 16 and 18 only. It does not protect against genital warts and offers narrower strain coverage than the quadrivalent options, but remains a clinically appropriate choice for females aged 9 to 25 where the primary focus is cervical cancer prevention.

Who Should Get Vaccinated, When, and How Many Doses

The most effective age for HPV vaccination is between 9 and 14 years. Girls vaccinated in this window require only two doses, administered 6 months apart, and generate immune responses that are substantially stronger and more durable than those produced in older age groups. The two-dose schedule for this age group is not a simplified course. It is a biologically appropriate regimen supported by robust clinical evidence.

From age 15 onward, a three-dose schedule is required, following a 0, 2, and 6 month timeline. The additional dose compensates for the modestly reduced immune response seen in older adolescents and adults. Cervavac Vaccine is approved for females in this group up to age 26. Gardasil Injection covers females and males up to age 45.

Adults who were not vaccinated in adolescence may still benefit, particularly if they have not been exposed to all strains covered by the vaccine. A gynaecologist or general physician can evaluate whether vaccination is appropriate based on age, history, and individual risk factors. The benefit is most certain for younger, vaccine-naive individuals, but the question is worth raising with a healthcare provider regardless of age.

How India Is Expanding Access to HPV Vaccination

A significant milestone in India's public health approach to cervical cancer was the inclusion of the HPV vaccine in the Universal Immunisation Programme, announced in the 2023 Union Budget and implemented as a phased national rollout targeting girls aged 9 to 14 years. This decision formalised what several state governments, including Sikkim, Punjab, and Delhi, had already been doing through their own school-based vaccination initiatives.

The government has primarily adopted Cervavac for this programme, given its domestic origin, regulatory approval, and substantially lower cost compared to imported formulations. The goal is to establish a baseline of HPV vaccination coverage across the adolescent female population before HPV exposure begins, complementing existing cervical cancer screening efforts run through the National Programme for Non-Communicable Diseases.

For families accessing vaccination through private healthcare, both Cervavac Vaccine and Gardasil Injection remain available through obstetricians, gynaecologists, paediatricians, and licensed pharmacies. The choice between them, particularly between Cervavac and Gardasil 9, typically comes down to the breadth of strain coverage desired, age, gender, and the practical considerations of cost and availability.

Why Screening Remains Critical Alongside Vaccination

A common misconception following vaccination is that cervical screening is no longer necessary. This is clinically incorrect, and it is worth being explicit about why.

No currently available HPV vaccine protects against every oncogenic strain. Even Gardasil 9, which covers nine strains, leaves a residual fraction of cervical cancers unaddressed. Additionally, vaccines offer no protection against strains to which a woman was already exposed before vaccination. Women who were vaccinated as adults, or who had any prior HPV exposure, may still carry oncogenic strains that their vaccination cannot address.

Cervical screening, whether through Pap smear cytology or HPV DNA testing, detects abnormal cellular changes in the cervix regardless of the HPV strain responsible. It is the safety net that catches what vaccination cannot prevent, and it remains the most reliable method for detecting cervical precancerous lesions early, when treatment is simplest and outcomes are best.

Women should begin cervical screening at around age 21 or within a few years of becoming sexually active, and continue at intervals recommended by their doctor throughout their adult life. The National Cancer Grid of India recommends HPV DNA testing over Pap smears as the preferred primary screening method where resources allow, given its higher sensitivity. Vaccination and screening are not alternatives to each other. They address different parts of the cervical cancer prevention pathway, and both are necessary.

Common Barriers to Vaccination in India and How to Address Them

Despite the availability of effective vaccines and government support for HPV immunisation, several barriers continue to limit uptake across India.

Awareness remains the most significant challenge. Studies across Indian states have consistently found that a large proportion of parents and young women are unaware of the link between HPV and cervical cancer, or of the existence of preventive vaccines. Addressing this requires clear, plain-language communication through healthcare providers, community health workers, and public health campaigns, particularly in regional languages.

Stigma associated with the sexually transmitted nature of HPV also leads some families to avoid or delay vaccination out of a misplaced concern that it implies something about their daughter's behaviour or future. HPV vaccination is a cancer prevention measure. The vaccine is given to children precisely because the immune response is strongest before exposure, and the purpose is entirely medical.

Cost remains a real barrier for families accessing vaccination through private channels, where Gardasil Injection carries a significantly higher price than Cervavac through government programmes. For families who wish to access Cervavac or Gardasil 9 through private pharmacies, understanding the price difference and discussing it with a doctor can help match the right product to both the clinical and practical circumstances.

What Is Worth Remembering

Cervical cancer is preventable. That is not a hopeful statement. It is a clinical fact, supported by decades of virology, immunology, and public health evidence. The tools required, a safe and effective HPV vaccine and regular cervical screening, both exist and are accessible in India today.

The first and most important step is vaccination in the 9-to-14 age window, before HPV exposure occurs and while the immune response is strongest. Cervavac Vaccine, available through India's national immunisation programme and private pharmacies alike, makes that step more accessible than it has ever been for Indian families. For those seeking broader strain coverage or vaccinating older individuals, Gardasil Injection provides a well-evidenced alternative with an extended age range.

Beyond vaccination, regular cervical screening throughout adulthood remains non-negotiable, and this message needs to reach women across every part of the country, not only those with easy access to urban gynaecological care.

Talking to a doctor, asking the right questions, and following through on both vaccination and screening are the practical steps that translate what is scientifically possible into actual lives protected.

Disclaimer: This article is for general informational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional for diagnosis, treatment, and guidance specific to your condition.